GuidelineMMWR. Morbidity and mortality weekly report2022
Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
Guideline in MMWR. Morbidity and mortality weekly report, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025.MMWR. Morbidity and mortality weekly report · 2025Guideline
- Vaccination of Adults With Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Guideline
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.Journal of addiction medicineGuideline
- Hepatitis B Virus: Epidemiology, Prophylaxis, Therapy, Clinical Outcomes, and Novel Therapeutic Directions.Biomolecules · 2026Review
- Ten tips for the first hemodialysis sessions.Clinical kidney journal · 2026Review
- Review
- Prevalence of Hepatitis B Coinfection in People With HIV by Birth-Year Cohort.Open forum infectious diseases · 2026Article
- Hepatitis B in the vaccine era: persistent burden and clinical implications.Clinical and experimental vaccine research · 2026Review
- Advancing Global Hepatitis B Elimination: The Case for Using Maize as a Low-Cost, Heat-Stable, and Scalable Oral Vaccine.Vaccines · 2026Review
- Hepatitis B Vaccination Coverage and Associated Factors Among Healthcare Workers: A Cross-Sectional Study.Health science reports · 2026Article
- Hepatitis B, C, and E viruses in solid organ transplantation: donor and recipient perspectives.JHLT open · 2026Article
- A Review of Human Immunodeficiency Virus and Hepatitis B Virus Co-Infection in Botswana.Viruses · 2026Review
- Review of Infections in Immunocompromised Travellers: Epidemiology, Infection Prevention and Management.Microorganisms · 2026Review
- Review
- Hepatitis B vaccination at birth: science, myths, and the safety net imperative.Frontiers in immunology · 2026Article
- Hepatitis B vaccination and post-exposure prophylaxis in healthcare workers - a comparative analysis of national and supranational recommendations.GMS hygiene and infection control · 2026Review
- Predictors of HPV and Hep B vaccination beliefs and behaviors among Vietnamese American young adults: Implications for dual vaccine coverage.Human vaccines & immunotherapeutics · 2025Article
- Insights into hepatitis B vaccination decision-making: Exploring vaccine preferences, health disparities, and practice patterns among patients and healthcare providers.Human vaccines & immunotherapeutics · 2025Article
- Awareness, Uptake, and Campaign Preferences for Hepatitis B Vaccination Among Adults in the United States Midwest.Mayo Clinic proceedings · 2025Article
- Factors Associated with Hepatitis B Vaccination Status Among U.S. Adults with Diabetes.Diseases (Basel, Switzerland) · 2025Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B (HepB) vaccines have demonstrated safety, immunogenicity, and efficacy during the past 4 decades (1,2). However, vaccination coverage among adults has been suboptimal, limiting further reduction in hepatitis B virus (HBV) infections in the United States. This Advisory Committee on Immunization Practices (ACIP) recommendation expands the indicated age range for universal HepB vaccination to now include adults aged 19-59 years. Removing the risk factor assessment previously recommended to determine vaccine eligibility in this adult age group (2) could increase vaccination coverage and decrease hepatitis B cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.